Boehringer & BridgeBio Seek EU Fast-Track Status; Enfortumab Vedotin Reverts To Standard Review
Executive Summary
Applications for the accelerated assessment of planned EU marketing applications for two drugs are being considered by the European Medicines Agency.
You may also be interested in...
Orphazyme Wants More Time To Deal With Late-Stage Issues For Arimoclomol In EU
Following Orphazyme’s disappointment in the US regarding its investigational drug for an ultrarare disease, the company has said it will need more time to address outstanding issues raised by EU reviewers about the same medicine.
Keeping Track: Novel Orphan Drugs Amondys 45, Nulibry Clear US FDA; First-Line NSCLC Claim For Libtayo
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
AdvaMed Launches Ethics Code To Meet ‘Business & Market Realities’ In India
Industry group AdvaMed says its Indian code on interactions between medtech companies and health care professionals is a first for the country.